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Calcium-activated Cl2 secretion is an important mod-
ulator of regulated ion transport in murine airway epi-
thelium and is mediated by an unidentified Ca21-stimu-
lated Cl2 channel. We have transfected immortalized
murine tracheal epithelial cells with the cDNA encoding
the permeabilizing P2X7 purinoreceptor (P2X7-R) to se-
lectively permeabilize the basolateral membrane and
thereby isolate the apical membrane Ca21-activated Cl2
current. In P2X7-R-permeabilized cells, we have demon-
strated that UTP stimulates a Cl2 current across the
apical membrane of CF and normal murine tracheal
epithelial cells. The magnitude of the UTP-stimulated
current was significantly greater in CF than in normal
cells. Ion substitution studies demonstrated that the
current exhibited a permselectivity sequence of Cl2 > I2
> Br2 > gluconate2. We have also determined a rank
order of potency for putative Cl2 channel blockers: ni-
flumic acid > 5-nitro-2-(3-phenylpropylamino)benzoic
acid > 4,4*-diisothiocyanostilbene-2,2*-disulfonate > gly-
benclamide >> diphenlyamine-2-carboxylate, tamoxifen,
and p-tetra-sulfonato-tetra-methoxy-calix[4]arene. Com-
plete characterization of this current and the corre-
sponding single channel properties could lead to the
development of a new therapy to correct the defective
airway surface liquid in cystic fibrosis patients.
Chloride secretion across the airway epithelium can be stim-
ulated by a number of secretogogues that activate distinct
second messenger transduction mechanisms (reviewed in Refs.
1 and 2). The cystic fibrosis (CF)1 gene product, the cystic
fibrosis transmembrane conductance regulator (CFTR), ac-
counts for the cAMP-regulated apical Cl2 conductance (3, 4).
There is, however, compelling evidence that a separate Ca21i-
activated apical Cl2 conductance (CaCC) exists. A large class of
ligands, including histamine (5, 6), bradykinin (7, 8), and ex-
tracellular ATP (9–11), has been shown to activate CaCC
across the apical membrane of airway epithelia. The unique
identity of this pathway in airway epithelia was established in
studies of CF nasal epithelia, which demonstrated that Ca21
ionophores are effective Cl2 secretogogues in CF tissues (12–
14). Moreover, in the airways of the CFTR(2/2) knockout
mouse, which definitively lacks CFTR (15), not only is the
CaCC pathway preserved, but it appears to be up-regulated
(16).
In the airway epithelium, Cl2 secretion is dependent on the
development of a favorable driving force, because at basal
conditions Cl2 is at or near electrochemical equilibrium across
the apical membrane. Ca21i can stimulate Cl
2 secretion by
multiple mechanisms. Elevation of Ca21i can directly activate
an apical membrane-localized Cl2 conductance and thereby
stimulate an apical exit pathway for Cl2 secretion. Ca21 mo-
bilizing agents can also cause a hyperpolarization in the cell to
generate a driving force for Cl2 secretion across the apical
membrane by either (or both) inhibiting an apical membrane
Na1 conductance (17) or activating a basolateral K1 conduct-
ance. Thus study of Ca21i-activated Cl
2 conductance in the
apical membrane of a polarized epithelium requires a means to
identify the contributions of apical Cl2 conductance in isolation
from other actions.
Previous studies in non-polarized secretory epithelia, e.g.
airway epithelia or T84 cells plated as isolated or dissociated
cells, have shown outwardly rectifying Cl2 currents stimulated
by intracellular Ca21 and sensitive to 4,49-diisothiocyanostil-
bene-2,29-disulfonate (DIDS) (18–24). These descriptions have
included such a wide range of Cl2 channel characteristics that
no consensus on the characteristics of this channel can be
achieved (25–28). Recently, a family of putative CaCC genes
has been cloned (29–32). The single channel properties and the
cellular localization of these gene products, however, have not
yet been determined. Thus, no indisputably apical Ca21-acti-
vated Cl2 channel has been identified at either the molecular
or single channel level.
We have recently identified a CaCC current expressed in
immortalized CF and normal murine tracheal epithelial cell
lines (33). In the current study we used permeabilization of the
basolateral membrane to determine the basic biophysical prop-
erties of the CaCC current in a functionally isolated apical
membrane of airway epithelial cells. We have accomplished
basolateral permeabilization by a novel approach involving
stable transfection of the P2X7 purinoreceptor (P2X7-R) into
our murine CF tracheal epithelial cell line. The P2X7-R is
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unique within its family, because binding of nucleotides
(ATP42 is the preferred agonist) to this receptor results in the
formation of a membrane pore that is capable of conducting
molecules as large as 900 daltons (34, 35). The pore is not
ion-selective and allows for free diffusion of both cations and
anions. Thus, by application of ATP selectively to the basolat-
eral solution, we can selectively permeabilize this barrier.
We report here the characterization of CaCC in the apical
membrane of a CF tracheal epithelial cell line when activated
by different classes of Ca21i-mobilizing agents (UTP and iono-
mycin). We have determined the halide selectivity and inhibi-
tor sensitivity of this Cl2 current unambiguously localized to
the apical membrane. Importantly, these observations will pro-
vide us with the hallmark characteristics for comparison with
subsequent whole cell and single channel studies and will
enable us to evaluate CaCC candidate genes. A greater under-
standing of the characteristics and mechanism of regulation of
the CaCC pathway is essential for development of pharmaco-
logical therapies designed to use CaCC as an alternate Cl2
channel to replace the defective CFTR.
EXPERIMENTAL PROCEDURES
Cell Culture—These studies utilized the immortalized murine tra-
cheal epithelial cell line (MTE18) derived from the CFTR(2/2) knock-
out mouse, described previously (33). Cells were maintained and cul-
tured at 33 °C, the permissive temperature for the immortalizing tsA58
TAg activity (33) on “Transwell-col” culture inserts. Culture medium
consisted of a 1:1 mix of Ham’s F12 and 3T3 fibroblast-conditioned
medium supplemented with the following hormones: transferrin (2.5
mg/ml), insulin (5 mg/ml), epidermal growth factor (12.5 ng/ml), endo-
thelial cell growth supplement (1.875 mg/ml), triiodothyronine (15 nM),
hydrocortisone (0.5 mM), and CaCl2 (0.5 mM). Cells were harvested for
experimental studies by trypsinization and plated at high density (2 3
104 cells per mm2) onto tissue culture inserts (collagen matrix supports
with a 4.5-mm plating diameter) and evaluated for confluence by daily
monitoring of transepithelial resistance (RT) and potential difference
(VT). Only monolayers generating at least a 1.0-millivolt (mV) VT and a
100-Vzcm2 resistance (after the resistance of the permeable support is
subtracted) were used for Ussing chambers studies, typically 5–7 days
after plating.
Ussing Chamber Studies—Electrical measurements, i.e. VT, RT, and
short-circuit current (ISC), were made on cell monolayers mounted in
Ussing chambers. Monolayers were bathed in a Krebs bicarbonate
Ringer solution (KBR) on both the lumenal and the serosal sides.
Serosal Ca21 was buffered to 300 nM with the addition of EGTA
(achieved by the addition of 1 mM EGTA and 0.925 mM Ca21). Other
alterations to the bathing solutions are listed in the figure legends. All
bathing solutions were bubbled with 95% O2, 5% CO2 and maintained
at 37 °C. VT was clamped to zero and pulsed to 610 mV for a 0.5-s
duration every minute. Electrometer output was digitized online and
ISC, RT, and calculated transepithelial potential (VT) were displayed on
a video monitor and stored on a computer hard drive. Drugs were added
from concentrated stock solutions to either lumenal and/or serosal sides
of the tissue. To eliminate the contribution of apical Na1 channels,
amiloride (1024 M) was added to the lumenal bath at the outset of all
experiments. Data are expressed as mean 6 S.E. for the number of
experiments (n). Student’s t test was used to determine statistical
significance between means.
Permeabilization—Basolateral membrane permeabilization was
achieved by stable transfection of the recombinant P2X7-R (a generous
gift from Dr. George Dubyak) into the MTE18 cell line. A cDNA con-
struct of the P2X7-R was cloned into a retroviral expression vector with
a selectable puromycin-resistance gene. Infection of the MTE18 cell line
with this retroviral vector and selection of resistant colonies in puro-
mycin-containing media resulted in the identification of several cell
clones that were puromycin-resistant and were verified for expression
of P2X7-R. These P2X7-R-expressing cells were plated on membrane
supports and used for Ussing chamber studies.
Following recording of stable baseline ISC and RT (15–20 min in
symmetrical Cl2 KBR solutions), 1 mM ATP42 (UTP is not an agonist
for the P2X7-R) was added to the serosal solution and serosal Mg
21 was
reduced to 100 mM to activate the pore (divalent cations inhibit pore
formation). Following successful permeabilization, documented by a
drop in the ISC to 0 mA/cm
2, the lumenal solution was diluted by three
successive 1-ml replacements of KBR with a low Cl2 containing (4.8 mM
Cl2, 110 mM gluconate2) KBR. This maneuver generates a gradient for
Cl2 secretion with a serosal Cl2 concentration of 115 mM and a final
lumenal Cl2 concentration of '68 mM. Ca21i-mobilizing agents were
added to the lumenal solution after the final dilution step. Anion selec-
tivity was determined by a similar strategy used to generate the Cl2
gradients. Briefly, three successive 1-ml replacements of the lumenal
solution with a modified KBR solution containing a halide ion (I2, Br2)
were substituted for Cl2 (e.g. 4.8 mM Cl2, 110 mM I2). The inhibitor
profile of CaCC was determined by the addition of inhibitors to the
lumenal solution after the imposition of the Cl2 gradient and prior to
stimulation by UTP. All experiments consisted of alterations in the ion
composition of the mucosal or serosal solution, followed by CaCC acti-
vation by addition of lumenal UTP.
In a subset of experiments we used the a-toxin of Staphylococcus
aureus to permeabilize MTE18 or MTE7b (CFTR(1/2) cells) monolay-
ers not expressing the P2X7-R. 1000 units of a-toxin was introduced to
the serosal compartment bathing MTE18 or MTE7b monolayers and
monitored for ;60 min until the ISC dropped to 0 mA/cm
2, indicating
permeabilization. Subsequent dilutions and agonist additions were per-
formed as described for P2X7-R monolayers.
Data Analysis—In CF and normal airway epithelial cells, mucosal
nucleotides, ATP or UTP, acting via purinergic receptors cause an
increase in ISC by reducing the apical membrane resistance with little
or no effect on the basolateral or shunt resistance, i.e. by directly
activating an apical membrane conductance (11). All experiments were
performed under voltage clamp conditions (clamped to 0 mV) and in the
presence of a Cl2 gradient followed by the addition of mucosal UTP. Our
experimental protocol defines the CaCC current as DICaCC 5 IUTP 2
Igradient. Because the transepithelial potential is clamped to 0 mV, the
equilibrium potential for Cl2 can be calculated as ECl2 5 DICaCC DGCaCC
and is determined by the chemical driving force imposed as a result of
the Cl2 gradient. This measured ECl
2 should ideally equal the calcu-
lated ECl2 determined by the Nernst equation. We used the measured
Eion (Cl
2, Br2, I2) values to determine a permselectivity sequence.
Apparent differences between the measured Eion and Nernst equation-
calculated Eion values are likely caused by ion permeation and accumu-
lation in the unstirred layer closely adjacent to the membrane surface
(37).
Materials—All biochemicals used were obtained from commercial
sources and were of tissue culture grade or better.
RESULTS
Transfection and expression of P2X7-R in MTE18 cells fol-
lowed by incubation of monolayers with 1 mM ATP and 10 mM
ToPro-1-iodide (a membrane-impermeant dye that fluoresces
when bound to DNA, Mr 5 645) demonstrates efficient mem-
brane permeabilization (Fig. 1). Although cells exposed to ATP
for either 10 or 30 min showed distinct intracellular fluores-
FIG. 1. ATP-mediated permeabilization of the basolateral
membrane of P2X7-R monolayers. P2X7-R-expressing cells were ex-
posed to 10 mM ToPro-1-iodide in the absence (left two panels) or pres-
ence (right two panels) of 1 mM ATP for 10 or 30 min. Cells were
photographed on a fluorescence inverted microscope with identical ex-
posure times.
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cence (Fig. 1, right two panels), P2X7-R-expressing cells not
exposed to ATP showed no significant fluorescence beyond
background levels (Fig. 1, left two panels). Control MTE18 cells
or MTE18 cells expressing the control LISN vector, did not
show any intracellular fluorescence in response to a 30-min
exposure with 1 mM ATP (data not shown). We used this cell
line (murine tracheal CFTR(2/2) epithelial cells, expressing
P2X7-R) and selective permeabilization of the basolateral mem-
brane to characterize CaCC resident in the apical membrane of
airway epithelial cells.
Basolateral membrane permeabilization of murine tracheal
epithelial cells followed by imposition of a Cl2 gradient and
activation by mucosal UTP revealed the presence of an apical
membrane Cl2 current (Fig. 2). Application of a cell to lumen
Cl2 gradient resulted in a greater response in monolayers
exposed to serosal 1 mM ATP than to cells not permeabilized by
ATP (Fig. 2B, 34.4 6 9.2 versus 7.5 6 2.4 mA/cm2). Importantly,
addition of mucosal UTP to permeabilized cell monolayers was
still capable of stimulating an increase in ISC consistent with
Cl2 secretion (Fig. 2A, solid line trace, and Fig. 2B, right panel,
filled bar). Similar responses to both an imposed Cl2 gradient
and mucosal UTP addition (DISC 5 54 6 7.4 and 32.1 6 8.9
mA/cm2, n 5 8, respectively) were observed in MTE18 (CF)
monolayers permeabilized by S. aureus a-toxin. The magnitude
of the Cl2 secretory response to the purinergic agonist UTP
was significantly greater in a-toxin-permeabilized MTE18
preparations than in a-toxin-permeabilized MTE7B (normal)
preparations (32.1 6 8.9 mA/cm2, n 5 8; 10.9 6 3.7 mA/cm2, n 5
8, respectively, p , .001). Elevation of intracellular Ca21 by
inclusion of the ionophore, ionomycin (1 mM), showed a similar
ability to stimulate Cl2 secretion in permeabilized CF mono-
layers (25.8 6 6.6 mA/cm2, n 5 8).
We have used several solution changes to verify that the
observed current in MTE18-P2X7-R cells is a Cl
2 current. As
shown above (Fig. 2) Cl2 secretion (serosal to mucosal) is stim-
ulated by imposition of a chemical gradient (i.e. lower Cl2
concentration in the lumenal solution). Reversal of this gradi-
ent, by decreasing the serosal Cl2 concentration in permeabi-
lized preparations, results in stimulation of “Cl2 absorption”
(mucosal to serosal) (Fig. 3). When the Cl2 concentration in the
lumenal solution was maintained at 115 mM and the serosal
solution was sequentially reduced, an absorptive Cl2 current
was recorded (Fig. 3A). The magnitude of the response was
similar to the response observed for Cl2 secretion (Fig. 2) but in
the opposite direction (68.8 6 7.4 versus 54.1 6 8.2 mA/cm2,
respectively). Mucosal UTP was likewise able to augment this
basal level of Cl2 absorption by 18.2 6 15.8 mA/cm2. MTE18-
P2X7-R cells that were not permeabilized (not exposed to sero-
sal ATP) did not respond to the imposed absorptive gradient
(data not shown).
We also studied the magnitude of the Cl2 current when the
serosal Cl2 concentration was reduced to levels that approxi-
mate intracellular Cl2 (;35 mM). We then imposed an out-
FIG. 2. Characteristic CaCC current response in P2X7-R per-
meabilized MTE18 monolayers. A, typical ISC responses in P2X7-R-
expressing MTE18 monolayers permeabilized by 1-mm serosal ATP
(solid line) and non-permeabilized MTE18 monolayers (dashed line).
Both permeabilized and non-permeabilized monolayers were treated
similarly during the rest of the experimental protocol. Lumenal Cl2 was
successively diluted by replacement with a sodium gluconate solution to
achieve a final lumenal Cl2 concentration of 68 mM, and 10 mM UTP was
added to the lumenal solution (as indicated by the arrows). B, mean Cl2
current responses in permeabilized (filled bars) and non-permeabilized
(open bars) MTE18 monolayers. Gradient responses (left two bars)
represent the total ISC response following the final solution change. The
ISC in response to UTP (10 mM) addition following the imposition of the
Cl2 gradient is shown in the right two bars. Filled bars represent the
mean current response of P2X7-R monolayers exposed to serosal ATP
(permeabilized, n 5 13), and open bars represent P2X7-R monolayers in
the absence of serosal ATP (non-permeabilized, n 5 14). Values repre-
sent mean and S.E. for each condition.
FIG. 3. Effects of altering the Cl2 gradient in P2X7-R monolay-
ers. A, dilution of the serosal Cl2 concentration generates a mucosal to
serosal Cl2 current. All bars represent P2X7-R monolayers permeabi-
lized by 1 mM serosal ATP. Cl2 gradients were generated as described
above (i.e. dilution of either the lumenal or serosal solution to achieve a
Cl2 concentration ratio of 115 mM to 68 mM). Filled bars (n 5 10)
represent monolayers with 115 mM mucosal Cl2 and 68 mM serosal Cl2
concentrations, and open bars (n 5 13) represent monolayers with 115
mM serosal Cl2 and 68 mM mucosal Cl2 concentration. The response to
10 mM lumenal UTP following the generation of the Cl2 gradient is
shown in the right two bars. B, Cl2 secretion induced with lower serosal
Cl2 concentrations. All conditions contain 35 mM Cl2 in the serosal
solution and a final mucosal Cl2 concentration of '20 mM. Filled bars
represent the mean current response of P2X7-R monolayers exposed to
serosal ATP (permeabilized, n 5 11), and open bars represent P2X7-R
monolayers in the absence of serosal ATP (non-permeabilized, n 5 18).
The ISC response to 10 mM lumenal UTP is shown in the right two bars.
Values represent mean and S.E. for each condition.
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wardly directed Cl2 gradient by reducing lumenal Cl2 to a
similar ratio as previously studied (final mucosal Cl2 was
diluted to a value of approximately 56% of the serosal concen-
tration). Under these conditions, UTP was still capable of stim-
ulating a characteristically similar Cl2 response, although the
magnitude of the response was smaller than that observed with
higher Cl2 concentrations (Fig. 3B).
The previous series of experiments involved dilution of the
Cl2 concentration by substitution with the less permeant anion
gluconate2. This in effect results in a bi-ionic permselectivity
relation, which provides an opportunity to determine the rela-
tive permeabilities of Cl2 and gluconate. We subsequently per-
formed similar experiments in which Cl2 was substituted with
Br2 or I2 (Fig. 4). Substitution of Cl2 with gluconate showed an
increase in secretory Cl2 current (serosal to mucosal) as ex-
pected for a Cl2 dominated current. Both bromide and iodide
substitution significantly attenuated the magnitude of this cur-
rent, indicating that both of these halides, I2 and Br2 were
more permeable than gluconate but less permeable than Cl2.
Simply considering the Cl2 concentration on either side of the
membrane, the Nernst equation would predict an equilibrium
potential of 213.6 mV. With gluconate as the counterion, we
calculated an ECl
2 of '29.8 mV. When bromide was substi-
tuted for Cl2, the calculated ECl
2 was '26.7 mV, and when
iodide was used as the counterion, ECl
2 was calculated to be
'23.8 mV. These increasing differences away from the Nernst
equilibrium potential describe an anion selectivity sequence
that is Cl2 . I2 . Br2 . gluconate2.
Several putative Cl2 channel blockers were investigated for
inhibition of UTP-stimulated Cl2 secretion in P2X7-R-perme-
abilized MTE18 cells (Fig. 5). The most efficacious compounds
appeared to be niflumic acid (NFA) (100 mM) and 59-nitrophe-
nyl-propylbenzoate (NPPB; 100 mM), both of which inhibited
approximately 90% of the CaCC-mediated current. The most
routinely used Cl2 channel blocker, DIDS (100 mM), inhibited
slightly more than 60% of the UTP-stimulated current,
whereas glybenclamide (100 mM), a K1 channel blocker that
has been shown to have efficacy against CFTR (38), blocked
about 40% of the UTP-stimulated current. Finally, TS-TM
calixarene (1 mM), a reported inhibitor specific for the outward
rectifying Cl2 channel (36), the anti-estrogen tamoxifen (10
mM), shown to inhibit the human ClCA2 channel (32), and
diphenylamine-2-carboxylate (DPC) (100 mM) were essentially
without effect (,10% inhibition) on the UTP-stimulated
current.
DISCUSSION
We have previously shown that UTP, ionomycin, and thap-
sigargin are all capable of stimulating a Cl2 current in both CF
and normal murine airway epithelial cells (33). In that study
we demonstrated the presence of the Ca21-activated Cl2 cur-
rent and noted that the magnitude of the current was greater
in CF (MTE18) than in normal (MTE7b) cells. In this study we
have used permeabilization of the basolateral membrane to
focus on an “apically isolated” preparation. Efficacy of perme-
abilization is apparent by the greater response to the imposed
gradient observed in the permeabilized versus non-permeabi-
lized preparations (compare filled with open bars in Fig. 2B).
Dilutions of the lumenal solution in non-permeabilized mono-
layers leads to only minor changes in current, but subsequent
addition of UTP generates a large change in current. In per-
meabilized preparations, a large increase in current is observed
in response to both changes in the Cl2 concentration, as well as
the addition of UTP. Importantly, nucleotides ATP/UTP acting
via the purinoreceptor, P2Y2, have been shown to directly re-
duce the apical membrane resistance with no effect on the
resistance of the tight junction (11). In our experimental de-
sign, imposition of a chemical gradient for Cl2 is likely to have
effects on both the apical membrane conductance and the para-
cellular pathway, but application of UTP will only stimulate
Cl2 secretion by activation of an apical membrane Cl2 channel.
Thus, the response to UTP following permeabilization and im-
position of the Cl2 gradient is convincing evidence for the
existence of a Ca21i-activated apical membrane Cl
2 channel.
Furthermore, an increase in ISC in response to ionomycin is
also confirmatory evidence that the Ca21i-mediated effects are
the result of an apical Cl2 conductance rather than an effect on
the paracellular pathway.
In an intact preparation, Ca21 activation of K1 channels in
the basolateral membrane likely plays an important role in
maintaining the driving force necessary for Cl2 secretion. One
obvious advantage of a permeabilized preparation is that we
can eliminate the need for basolateral K1 channels by imposing
a gradient by solution changes and thereby directly focus on
the apical membrane. With these maneuvers we have shown
that a Ca21i-activated Cl
2 conductance is present in the apical
FIG. 4. Halide selectivity sequence in P2X7-R monolayers. All
bars represent P2X7-R monolayers permeabilized by 1 mM serosal ATP
and contain 115 mM serosal Cl2. Mucosal solutions were diluted to
achieve a final Cl2 concentration of 68 mM with the replacement anion,
gluconate (open bars, n 5 11), bromide (filled bars, n 5 7), or iodide
(hatched bars, n 5 12). Total lumenal anion concentrations were always
maintained at 115 mM (e.g. 68 mM Cl2 and 47 mM gluconate). Values
represent mean 6 S.E. for each condition. The asterisk represents
statistical significance (p , 0.01) as determined by the Student’s t test
between gluconate and bromide means and gluconate and iodide
means.
FIG. 5. Inhibitor effects on Cl2 currents measured in P2X7-R-
permeabilized monolayers. All monolayers were permeabilized by 1
mM serosal ATP and exposed to the serosal to mucosal Cl2 gradient as
described above. Inhibitors, DIDS (100 mM, n 5 8), DPC (100 mM, n 5 8),
glybenclamide (100 mM, n 5 8), NFA (100 mM, n 5 8), NPPB (100 mM,
n 5 8), tamoxifen (10 mM, n 5 8), and TS-TM calixarene (1 mM, n 5 9)
were added to the mucosal solution prior to addition of 10 mM UTP.
Values represent mean 6 S.E. of percentage inhibition of the UTP
response in comparison to permeabilized monolayers treated with ve-
hicle alone prior to UTP.
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membrane of murine tracheal epithelial cells. Interestingly,
UTP and ionomycin regulate this apical membrane Cl2 con-
ductance even when Ca21i is buffered to moderate levels (300
nM) by EGTA. This suggests that the accessory proteins neces-
sary for regulation are not dialyzed by permeabilization and
that the mechanisms for intracellular Ca21 release are also
well preserved. Somewhat surprising, however, was the obser-
vation that UTP consistently activated this Cl2 conductance in
the presence of 1 mM EGTA. EGTA is relatively slow in terms
of buffering Ca21 and may not be able to rapidly chelate release
from local Ca21 stores efficiently (39, 40). This experimental
protocol allows us to buffer Ca21 to physiological levels and
preserves the ability to observe a UTP-mediated current re-
sponse. These data are consistent with whole cell patch clamp
studies that showed ATP-activated Cl2 currents in human
airway epithelial cells in the presence of 10 mM EGTA (41). We
have previously shown that UTP-stimulated currents in non-
permeabilized MTE18 cells can be abolished by BAPTA-AM
(33). Together, these results suggest that the UTP-stimulated
current is Ca21-dependent, but that released Ca21 is capable of
activating a target before it can be chelated by EGTA.
Heterologous expression of P2X7-R in MTE18 cells provides a
reliable, consistent, and rapid technique to generate an apically
isolated preparation. Characteristically, the Cl2 secretory re-
sponse to the imposed Cl2 gradient and to the lumenal addition
of UTP is similar to the responses observed in a-toxin perme-
abilized monolayers. Challenging P2X7-R-expressing monolay-
ers with ATP and the fluorescent DNA-intercalating agent,
ToPro-1-iodide, demonstrated that P2X7-R effectively forms a
pore sufficient for dialysis of the intracellular ion solution.
These studies show that nearly every cell was expressing
P2X7-R and that receptor expression alone did not confer an
increase in cell conductance, but rather that receptor occu-
pancy by ATP was an absolute requirement for pore formation.
Reversal of the Cl2 gradient confirmed that the preparation
was permeabilized and also established that the current was
Cl2-selective. Stable expression of P2X7-R allows us an oppor-
tunity to determine the characteristics of the Ca21i-activated
Cl2 conductance of the apical membrane in CF murine tracheal
epithelial cells. This novel protocol for membrane permeabili-
zation (transfection and activation of P2X7-R) has the further
advantage of serving as a self-contained control for permeabi-
lization. By not exposing the cells to millimolar basolateral
ATP, the cells function as an intact monolayer, thus the same
monolayer preparation can be used for both non-permeabilized
and permeabilized protocols.
We have characterized apical membrane CaCC in these
preparations in terms of ion selectivity and inhibitor sensitiv-
ity. As mentioned earlier, several reports have provided differ-
ing characteristics for the CaCC. We believe that characteriza-
tion in the CF murine airway apical membrane will provide the
hallmark characteristics for this channel for subsequent whole
cell and single channel analyses. Initial studies in P2X7-R-
permeabilized monolayers (Figs. 2 and 3) demonstrated a Cl2
current in response to a gradient that was generated by partial
replacement of the mucosal Cl2 with the less permeant anion,
gluconate. Although this fundamentally important experiment
demonstrates the presence of the apical membrane Cl2 con-
ductance, it also in fact serves as the first in a series of ion
replacement studies. Although gluconate is often used as an
“impermeant” anion, it is really only less permeant than the
halide series. Therefore, a bi-ionic solution of Cl2 and gluconate
can be evaluated for permselectivity based on the magnitude of
the current response and a calculated equilibrium potential. As
observed in Fig. 4, not surprisingly, Cl2 is more permeant than
gluconate and results in a Cl2 current from serosal to mucosal
solution. In contrast, when the mucosal Cl2 is partially re-
placed with iodide or bromide, we observed a smaller UTP-
induced secretion and a greater shift from the ideal equilibrium
potential, suggesting an ion series for this apical Cl2 conduct-
ance of Cl2 . I2 . Br2 . gluconate2. This anion selectivity
sequence is somewhat similar to other reports of Ca21-acti-
vated Cl2 channels (14, 41–43) but importantly differs from
the selectivity sequence for CFTR (3, 4, 14, 42) or from the CLC
superfamily of Cl2 channels (44).
Cl2 channel blockers were investigated to determine a “sen-
sitivity sequence” for the CaCC channel. Pretreatment of per-
meabilized monolayers with the Cl2 channel blockers was used
to determine a percentage inhibition of the UTP-mediated Cl2
current. The rank order of potency for channel inhibitors ap-
pears to be NFA, NPPB ('90%) . DIDS ('60%) . glyben-
clamide (' 40%) .. tamoxifen, TS-TM calixarene, and DPC
(0–10%). The very low, nearly non-existent effect of TS-TM
calixarene was consistent with previous studies that defined
this compound as a specific inhibitor of the outward rectifying
Cl2 channel (36). The moderate effect of glybenclamide on
CaCC was a bit surprising, because this sulfonylurea com-
pound was thought to be fairly specific for K-ATP and CFTR
channels (45, 46). In many studies DIDS is reported to be a
highly effective inhibitor of Ca21-activated Cl2 conductance
(18–20, 41, 47), and although we observed moderate inhibition,
it was not as effective as NFA. Higher doses of DIDS may
generate higher levels of inhibition, but we are sensitive to the
concerns of cross-linking that are associated with this com-
pound. In our studies NFA was the most potent inhibitor of
CaCC but like many Cl2 channel blockers lacks specificity, as
it has been shown to also inhibit CFTR in human airways (47,
48). These studies serve to confirm the notion that Cl2 channel
blockers are notoriously nonspecific, and inhibitor studies
should be used simply as another characteristic to define the
observed current. That is, an inhibitor order of potency or
sensitivity sequence should serve an analogous function as a
halide permselectivity sequence. The identity of the current
should be defined by a combination of those characteristic
sequences rather than any single effect.
Tamoxifen has recently been shown to have inhibitory effects
against the human ClCA2 channel (32). Interestingly, tamox-
ifen was without effect in our CF murine tracheal epithelial
cells. Furthermore, we have not been able to detect the murine
homologue of this channel, mClCA1, by Northern blot analysis
in our CF murine tracheal epithelial cells, suggesting that the
apical membrane Ca21i-activated Cl
2 conductance is mediated
by a thus far unidentified gene or protein.
We propose to utilize the activation, inhibition, and selectiv-
ity characteristics determined in this study for future experi-
ments studying whole cell currents and single channel proper-
ties and ensure that the channel characteristics are consistent
at each level of investigation. This systematic approach will
result in the unambiguous identification of the murine airway
CaCC localized to the apical membrane. Identification of CaCC
along with a determination of regional distribution within the
lung will permit us to develop strategies to activate CaCC and
stimulate Cl2 and fluid secretion and thereby ameliorate the
dehydration that is foremost in the pathology of cystic fibrosis.
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